FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031340028> ?p ?o ?g. }

• W2031340028 endingPage "355" @default.
• W2031340028 startingPage "349" @default.
• W2031340028 abstract "The selective cyclooxygenase-2 (COX-2) inhibitors celecoxib and rofecoxib are now widely prescribed instead of the traditional nonsteroidal antiinflammatory agents (NSAIDs). Short-term randomized controlled trials (RCTs) documented that both agents were superior to placebo, with comparable efficacy and better upper gastrointestinal (GI) adverse-event profiles than traditional NSAIDs, including ibuprofen, naproxen, and diclofenac. However, these RCTs were not powered to demonstrate GI tolerability equivalent to placebo, and consequently the GI warning common to the NSAID class remained in both celecoxib and rofecoxib labels. The Celecoxib Long-term Arthritis Safety Study (CLASS) and the Vioxx Gastrointestinal Outcomes Research (VIGOR) trials were designed to demonstrate GI safety superior to that of traditional NSAIDs, as used in regular clinical practice, assessed by “clinically meaningful” upper GI events, at twice recommended clinical doses for long-term use (celecoxib 400 mg twice daily; rofecoxib 50 mg daily) (1,2). Although both large outcome trials shared similar designs, they differed in several important aspects (Table 1). Comparator NSAIDs in CLASS were ibuprofen and diclofenac, and in VIGOR it was naproxen. Only patients with rheumatoid arthritis (RA) were enrolled in VIGOR; in CLASS, RA patients represented 28% of the study population, and osteoarthritis (OA) patients represented the other 72%. Enrolled patient numbers were similar: in CLASS, 3,987 patients took celecoxib, 1,996 patients took diclofenac (75 mg twice daily), and 1,985 patients took ibuprofen (800 mg 3 times daily); in VIGOR 4,047 patients took rofecoxib and 4,029 took naproxen (500 mg twice daily). Patient populations differed at baseline predominantly by risk factors for cardiovascular (CV) and GI events (Table 2). Enrollment of patients taking prophylactic lowdose aspirin ( 325 mg/day) or other antiplatelet agents (such as ticlopidine) was permitted in CLASS and proscribed in VIGOR. Patients with angina or congestive heart failure with symptoms at rest or with minimal activity were excluded from participation in VIGOR. The population enrolled in CLASS included more patients at risk for thromboembolic CV disease. During presentations at the FDA Arthritis Advisory Committee meetings, February 7–8, 2001, where results of the CLASS and the VIGOR trial were reviewed, CV safety issues potentially associated with administration of COX-2 selective agents were raised (3,4). This editorial will discuss these data and possible explanations for the findings." @default.
• W2031340028 created "2016-06-24" @default.
• W2031340028 creator A5012283576 @default.
• W2031340028 creator A5026165132 @default.
• W2031340028 date "2002-08-12" @default.
• W2031340028 modified "2023-10-16" @default.
• W2031340028 title "The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors" @default.
• W2031340028 cites W1565253767 @default.
• W2031340028 cites W1972566357 @default.
• W2031340028 cites W1972821304 @default.
• W2031340028 cites W1977473142 @default.
• W2031340028 cites W1985543382 @default.
• W2031340028 cites W1986003353 @default.
• W2031340028 cites W1995355693 @default.
• W2031340028 cites W1998651384 @default.
• W2031340028 cites W2001162433 @default.
• W2031340028 cites W2011119068 @default.
• W2031340028 cites W2011327495 @default.
• W2031340028 cites W2020563114 @default.
• W2031340028 cites W2024233889 @default.
• W2031340028 cites W2040222397 @default.
• W2031340028 cites W2073833391 @default.
• W2031340028 cites W2077143685 @default.
• W2031340028 cites W2082001748 @default.
• W2031340028 cites W2084394836 @default.
• W2031340028 cites W2092193486 @default.
• W2031340028 cites W2114949308 @default.
• W2031340028 cites W2118794261 @default.
• W2031340028 cites W2136486607 @default.
• W2031340028 cites W2137408480 @default.
• W2031340028 cites W2143995569 @default.
• W2031340028 cites W2145816148 @default.
• W2031340028 cites W2149233326 @default.
• W2031340028 cites W2158192553 @default.
• W2031340028 cites W2163756514 @default.
• W2031340028 cites W2188507800 @default.
• W2031340028 cites W2330496155 @default.
• W2031340028 cites W4232411700 @default.
• W2031340028 cites W4239471829 @default.
• W2031340028 cites W4245466284 @default.
• W2031340028 cites W4252241269 @default.
• W2031340028 cites W61709055 @default.
• W2031340028 doi "https://doi.org/10.1002/art.10560" @default.
• W2031340028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12209478" @default.
• W2031340028 hasPublicationYear "2002" @default.
• W2031340028 type Work @default.
• W2031340028 sameAs 2031340028 @default.
• W2031340028 citedByCount "73" @default.
• W2031340028 countsByYear W20313400282012 @default.
• W2031340028 countsByYear W20313400282013 @default.
• W2031340028 countsByYear W20313400282016 @default.
• W2031340028 countsByYear W20313400282017 @default.
• W2031340028 countsByYear W20313400282021 @default.
• W2031340028 countsByYear W20313400282022 @default.
• W2031340028 countsByYear W20313400282023 @default.
• W2031340028 crossrefType "journal-article" @default.
• W2031340028 hasAuthorship W2031340028A5012283576 @default.
• W2031340028 hasAuthorship W2031340028A5026165132 @default.
• W2031340028 hasConcept C126322002 @default.
• W2031340028 hasConcept C164705383 @default.
• W2031340028 hasConcept C181199279 @default.
• W2031340028 hasConcept C185592680 @default.
• W2031340028 hasConcept C2779689624 @default.
• W2031340028 hasConcept C2909020919 @default.
• W2031340028 hasConcept C55493867 @default.
• W2031340028 hasConcept C71924100 @default.
• W2031340028 hasConceptScore W2031340028C126322002 @default.
• W2031340028 hasConceptScore W2031340028C164705383 @default.
• W2031340028 hasConceptScore W2031340028C181199279 @default.
• W2031340028 hasConceptScore W2031340028C185592680 @default.
• W2031340028 hasConceptScore W2031340028C2779689624 @default.
• W2031340028 hasConceptScore W2031340028C2909020919 @default.
• W2031340028 hasConceptScore W2031340028C55493867 @default.
• W2031340028 hasConceptScore W2031340028C71924100 @default.
• W2031340028 hasIssue "4" @default.
• W2031340028 hasLocation W20313400281 @default.
• W2031340028 hasLocation W20313400282 @default.
• W2031340028 hasOpenAccess W2031340028 @default.
• W2031340028 hasPrimaryLocation W20313400281 @default.
• W2031340028 hasRelatedWork W1998046748 @default.
• W2031340028 hasRelatedWork W2017251681 @default.
• W2031340028 hasRelatedWork W2071148731 @default.
• W2031340028 hasRelatedWork W2265299681 @default.
• W2031340028 hasRelatedWork W2597092979 @default.
• W2031340028 hasRelatedWork W2610810862 @default.
• W2031340028 hasRelatedWork W2977667965 @default.
• W2031340028 hasRelatedWork W2119580014 @default.
• W2031340028 hasRelatedWork W2620786107 @default.
• W2031340028 hasRelatedWork W3029160838 @default.
• W2031340028 hasVolume "47" @default.
• W2031340028 isParatext "false" @default.
• W2031340028 isRetracted "false" @default.
• W2031340028 magId "2031340028" @default.
• W2031340028 workType "article" @default.